Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBUSH Study: Bortezomib and Pembrolizumab ± Pelareorep in Relapsed Multiple Myeloma
NCT05514990Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pelareorep in multiple myeloma (MM), sponsored by University of Southern California. Started Oct 2022; status: active, not recruiting.
02
Drugs
pelareorep
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05514990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514990.